In a report released today, Jonathan Aschoff from Roth MKM maintained a Buy rating on Aptevo Therapeutics (APVO – Research Report), with a ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--SiteOne Therapeutics, Inc., a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other ...

Shares of CRISPR Therapeutics have struggled amid less-than-stellar sales of its Casgevy therapy. The company's gene-editing biotechnology holds much promise but still faces significant uncertainties.

In recent trading, Aptevo Therapeutics Inc (APVO) stock price has shown some volatility, fluctuating -43.59% over the last five trades and -44.63% over the past 30 trades. This represents a notable ...

Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) (“Aptevo” or the “Company”), a clinical-stage biotechnology company focused on developing novel immune-oncology ...